Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Sznol

Showing results (31-40 of 188) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusionScott Wadler, Della Makower, Caroline Clairmont, et al.
The Oncologist|November 16, 2023
Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint InhibitorsAdriana M Kahn, Curtis J Perry, Katrina Etts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2011
White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapyJeffrey Weber, Michael Atkins, Patrick Hwu, et al.
Cornea|January 16, 2016
Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal PerforationAlexander T Nguyen, Maxwell Elia, Miguel A Materin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2018
Introducing a New Series: Immunotherapy Facts and HopesIgnacio Melero, Mario Sznol, Marlowe S Tessmer, et al.
Cancer Chemotherapy and Pharmacology|November 24, 2016
Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignanciesCharles A Kunos, Edward Chu, Jan H Beumer, et al.
Investigational New Drugs|March 4, 2005
A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancerJohn Murren, Manuel Modiano, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2003
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumorsJohn Murren, Manuel Modiano, Caroline Clairmont, et al.
Frontiers in Oncology|April 20, 2017
Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor CancersCharles A Kunos, Edward Chu, Della Makower, et al.
Digital Journal of Ophthalmology : DJO|September 20, 2017
A 71-year-old woman with decreased vision, nyctalopia, and peripheral vision lossRavi Parikh, Miguel A Materin, Robert Lesser, et al.
Pageof 19

Showing results (31-40 of 188) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusionScott Wadler, Della Makower, Caroline Clairmont, et al.
The Oncologist|November 16, 2023
Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint InhibitorsAdriana M Kahn, Curtis J Perry, Katrina Etts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2011
White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapyJeffrey Weber, Michael Atkins, Patrick Hwu, et al.
Cornea|January 16, 2016
Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal PerforationAlexander T Nguyen, Maxwell Elia, Miguel A Materin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2018
Introducing a New Series: Immunotherapy Facts and HopesIgnacio Melero, Mario Sznol, Marlowe S Tessmer, et al.
Cancer Chemotherapy and Pharmacology|November 24, 2016
Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignanciesCharles A Kunos, Edward Chu, Jan H Beumer, et al.
Investigational New Drugs|March 4, 2005
A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancerJohn Murren, Manuel Modiano, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2003
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumorsJohn Murren, Manuel Modiano, Caroline Clairmont, et al.
Frontiers in Oncology|April 20, 2017
Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor CancersCharles A Kunos, Edward Chu, Della Makower, et al.
Digital Journal of Ophthalmology : DJO|September 20, 2017
A 71-year-old woman with decreased vision, nyctalopia, and peripheral vision lossRavi Parikh, Miguel A Materin, Robert Lesser, et al.
Pageof 19